Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H19F5N2O.ClH |
Molecular Weight | 434.831 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.FC(F)C(F)(F)COC1=CC(CNCCC2=CNC3=C2C=CC(F)=C3)=CC=C1
InChI
InChIKey=KXOQNPANAFXKTN-UHFFFAOYSA-N
InChI=1S/C20H19F5N2O.ClH/c21-15-4-5-17-14(11-27-18(17)9-15)6-7-26-10-13-2-1-3-16(8-13)28-12-20(24,25)19(22)23;/h1-5,8-9,11,19,26-27H,6-7,10,12H2;1H
Molecular Formula | C20H19F5N2O |
Molecular Weight | 398.3697 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://adisinsight.springer.com/drugs/800019915Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/20569520 | https://www.ncbi.nlm.nih.gov/pubmed/27039041
Sources: http://adisinsight.springer.com/drugs/800019915
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/20569520 | https://www.ncbi.nlm.nih.gov/pubmed/27039041
Idalopirdine (Lu AE58054) is a Serotonin 6 receptor (5-HT6) antagonist. Idalopirdine exrets good oral bioavailability and robust efficacy in a rat model of cognitive impairment in schizophrenia. In rats idalopirdine potentiates the effects of acetylcholinesterase inhibitor donepezil on two pharmacodynamic biomarkers associated with cognition, i.e. neuronal oscillations and extracellular ACh levels in the hippocampus. Such potentiation could contribute to the procognitive effects of idalopirdine observed in donepezil-treated Alzheimer's disease patients. The compound is being developed by Lundbeck as an adjunctive therapy with acetylcholinesterase inhibitor donepezil, and is in phase III development for the treatment of Alzheimer's disease in multiple countries worldwide. A phase II trial for the treatment of cognitive impairment associated with schizophrenia was conducted; however no recent reports of development for idalopirdine have been identified.
Originator
Sources: http://adisinsight.springer.com/drugs/800019915
Curator's Comment: # Eli Lilly
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3371 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20569520 |
0.83 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
30 mg 3 times / day multiple, oral Studied dose Dose: 30 mg, 3 times / day Route: oral Route: multiple Dose: 30 mg, 3 times / day Sources: Page: p.1096 |
unhealthy, ADULT n = 145 Health Status: unhealthy Condition: Alzheimer disease Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 145 Sources: Page: p.1096 |
Other AEs: Gamma-glutamyltransferase increased, Alanine aminotransferase increased... Other AEs: Gamma-glutamyltransferase increased (10%) Sources: Page: p.1096Alanine aminotransferase increased (6%) Aspartate aminotransferase increased (4%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Gamma-glutamyltransferase increased | 10% | 30 mg 3 times / day multiple, oral Studied dose Dose: 30 mg, 3 times / day Route: oral Route: multiple Dose: 30 mg, 3 times / day Sources: Page: p.1096 |
unhealthy, ADULT n = 145 Health Status: unhealthy Condition: Alzheimer disease Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 145 Sources: Page: p.1096 |
Aspartate aminotransferase increased | 4% | 30 mg 3 times / day multiple, oral Studied dose Dose: 30 mg, 3 times / day Route: oral Route: multiple Dose: 30 mg, 3 times / day Sources: Page: p.1096 |
unhealthy, ADULT n = 145 Health Status: unhealthy Condition: Alzheimer disease Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 145 Sources: Page: p.1096 |
Alanine aminotransferase increased | 6% | 30 mg 3 times / day multiple, oral Studied dose Dose: 30 mg, 3 times / day Route: oral Route: multiple Dose: 30 mg, 3 times / day Sources: Page: p.1096 |
unhealthy, ADULT n = 145 Health Status: unhealthy Condition: Alzheimer disease Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 145 Sources: Page: p.1096 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
inconclusive [IC50 25.929 uM] | ||||
yes [IC50 0.0477 uM] | yes (co-administration study) Comment: Increased donepezil bioavailability by 10% |
|||
yes [IC50 13.4504 uM] | ||||
yes [IC50 9.5221 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | ||||
yes |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25297016
Idalopirdine 90 mg per day (30 mg thrice daily) improved cognitive function in donepezil-treated patients with moderate Alzheimer's disease (NCT01019421).
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:04:17 GMT 2023
by
admin
on
Sat Dec 16 09:04:17 GMT 2023
|
Record UNII |
545BT5182Y
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID30610494
Created by
admin on Sat Dec 16 09:04:17 GMT 2023 , Edited by admin on Sat Dec 16 09:04:17 GMT 2023
|
PRIMARY | |||
|
467458-02-2
Created by
admin on Sat Dec 16 09:04:17 GMT 2023 , Edited by admin on Sat Dec 16 09:04:17 GMT 2023
|
PRIMARY | |||
|
DBSALT002112
Created by
admin on Sat Dec 16 09:04:17 GMT 2023 , Edited by admin on Sat Dec 16 09:04:17 GMT 2023
|
PRIMARY | |||
|
21071391
Created by
admin on Sat Dec 16 09:04:17 GMT 2023 , Edited by admin on Sat Dec 16 09:04:17 GMT 2023
|
PRIMARY | |||
|
545BT5182Y
Created by
admin on Sat Dec 16 09:04:17 GMT 2023 , Edited by admin on Sat Dec 16 09:04:17 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |